American Journal of Kidney Diseases
Volume 45, Issue 3 , Pages 531-539, March 2005

Nonsteroidal anti-inflammatory drugs and risk of ARF in the general population

  • Consuelo Huerta, MD

      Affiliations

    • Centro Español de Investigación Farmacoepidemiológica, Spanish Centre for Pharmacoepidemiologic Research, Madrid, Spain
    • Corresponding Author InformationAddress reprint requests to Consuelo Huerta Alvarez, MD, Centro Español de Investigación Farmacoepidemiológica (CEIFE), Almirante 28; 2°, 28004 Madrid, Spain
  • ,
  • Jordi Castellsague, MD

      Affiliations

    • Pfizer Global Epidemiology, Safety and Risk Management, Barcelona, Spain
  • ,
  • Cristina Varas-Lorenzo, MD, PhD

      Affiliations

    • Pfizer Global Epidemiology, Safety and Risk Management, Barcelona, Spain
  • ,
  • Luis Alberto García Rodríguez, MD

      Affiliations

    • Centro Español de Investigación Farmacoepidemiológica, Spanish Centre for Pharmacoepidemiologic Research, Madrid, Spain

Received 13 October 2004; accepted 2 December 2004. published online 28 January 2005.

Background: Most epidemiological studies evaluating the association between nonsteroidal anti-inflammatory drugs (NSAIDs) and acute renal failure (ARF) found an increased risk for developing ARF while taking NSAIDs. Despite these studies, little is known about the effect of dose and duration of therapy, risk of individual NSAIDs, comorbidity, or concomitant use of other nephrotoxic drugs. Methods: This is a nested case-control study using the General Practice Research Database from the United Kingdom. Participants were 386,916 patients aged 50 to 84 years on January 1, 1997, and free of known cancer, renal disorder, cirrhosis, or systemic connective tissue disease. After validation of cases identified from this cohort, 103 patients were confirmed as idiopathic cases of ARF and compared with 5,000 controls frequency matched by age and sex. Results: Current users of NSAIDs had a relative risk (RR) for ARF of 3.2 (95% confidence interval [CI], 1.8 to 5.8), and the risk declined after treatment was discontinued. Increased risk was present with both short- and long-term therapy and was slightly greater among users of high doses. History of heart failure (HF), hypertension, diabetes, and hospitalizations and consultant visits in the previous year were all associated with a greater risk for ARF. There was a suggestion of a modification of the effect of NSAIDs in patients with hypertension and those with HF. Use of selected cardiovascular drugs was associated with a 5-fold increase in risk for ARF. Diuretics presented the greatest risk. Risk increased with concomitant use of NSAIDs and diuretics (RR, 11.6; 95% CI, 4.2 to 32.2) and NSAIDs and calcium channel blockers (RR, 7.8; 95% CI, 3.0 to 20.5). Conclusion: NSAID users had a 3-fold greater risk for developing a first-ever diagnosis of clinical ARF compared with non–NSAID users in the general population. NSAIDs should be used with special caution in patients with hypertension and/or HF.

Index words:  Pharmacoepidemiology , nested case-control study , nonsteroidal anti-inflammatory drugs (NSAIDs) , acute renal failure (ARF)

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Originally published online as doi:10.1053/j.ajkd.2004.12.005 on January 26, 2005.

 Supported in part by an unrestricted research grant from Pfizer. The design and analysis of this study were made independently by Centro Español de Investigación Farmacoepidemiológica.

PII: S0272-6386(04)01619-1

doi:10.1053/j.ajkd.2004.12.005

American Journal of Kidney Diseases
Volume 45, Issue 3 , Pages 531-539, March 2005